Clinical Trials Browser

Phase 2 × Docetaxel × Genitourinary × Clear all

NCT07322263 2026-03-17

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT05848011 2026-03-16

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT07287150 2026-03-05

InavoPC

Phase 2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Prostatic Neoplasms

NCT03246347 2026-01-23

A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer

Phase 2 Active not recruiting

40 enrolled 12 charts

Prostatic Neoplasms

NCT04126070 2026-01-22

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Phase 2 Active not recruiting

Hormone Sensitive Prostate Cancer

NCT03456843 2026-01-21

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Phase 2 Active not recruiting

Stage IV Prostate Adenocarcinoma AJCC v7

NCT06734130 2026-01-21

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03556904 2026-01-15

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Phase 2 Completed

14 enrolled 16 charts

Prostatic Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT07268794 2025-12-08

CONVERT-HB1

Phase 2 Not yet recruiting

Adenocarcinoma, Prostatic Neoplasms

NCT05189457 2025-12-04

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04386746 2025-11-17

GEMDOCE

Phase 2 Active not recruiting

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04663997 2025-11-06

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03517969 2025-10-20

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

73 enrolled 14 charts

Prostatic Neoplasms

NCT06392841 2025-10-20

HARMONY

Phase 2 Withdrawn

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT04015622 2025-08-20

PROTRACT

Phase 2 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06632951 2025-08-11

LIVIGNO-3

Phase 2 Active not recruiting

Carcinoma, Transitional Cell, Neoplasms

NCT05005728 2025-07-17

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT04343885 2025-07-11

UpFrontPSMA

Phase 2 Active not recruiting

Metastatic Hormone Naive Prostate Cancer

NCT06663137 2025-06-13

HGNMIBC

Phase 2 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT03442556 2025-06-12

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

Phase 2 Terminated

ATM Gene Mutation

NCT03764540 2025-04-13

CABPOSTAAT

Phase 2 Terminated

Prostatic Neoplasms

NCT05024734 2025-03-11

GAIN INST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04812366 2024-12-16

GUNS

Phase 2 Recruiting

Prostatic Neoplasms

NCT03230734 2024-09-27

RAPSON

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00936936 2024-08-26

High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Phase 2 Completed

64 enrolled 10 charts

Testicular Neoplasms

NCT02649855 2024-08-06

Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer

Phase 2 Completed

74 enrolled 15 charts

Prostatic Neoplasms

NCT01446731 2024-07-03

Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer

Phase 2 Completed

43 enrolled 11 charts

Prostatic Neoplasms

NCT05762536 2024-06-27

DAROTAXEL

Phase 2 Recruiting

Metastatic Castration-resistant Prostate Cancer

NCT02453009 2024-05-30

CHEIRON

Phase 2 Completed

Prostatic Neoplasms

NCT06387056 2024-04-26

SEGNO

Phase 2 Recruiting

Locally Advanced Prostate Cancer

NCT04028388 2024-04-17

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Phase 2 Completed

135 enrolled 29 charts

Prostate Cancer Metastatic

NCT03700099 2024-04-15

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03311555 2024-03-19

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

Phase 2 Completed

39 enrolled 15 charts

Prostatic Neoplasms

NCT06227065 2024-01-26

POLO

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT00587431 2023-11-07

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Phase 2 Completed

102 enrolled 8 charts

Neoplasms, Prostatic Neoplasms

NCT00020046 2023-10-31

Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer

Phase 2 Completed

Neoplasms, Prostatic Neoplasms, Genetic Diseases, Inborn

NCT03737123 2023-09-13

Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2 Terminated

6 enrolled 18 charts

Carcinoma, Transitional Cell

NCT00786682 2023-08-14

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

Phase 2 Terminated

11 enrolled 7 charts

Prostatic Neoplasms

NCT00258388 2023-08-04

Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2 Completed

Prostatic Neoplasms

NCT01619813 2023-08-04

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00004223 2023-06-18

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT02516670 2023-06-07

Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer

Phase 2 Terminated

50 enrolled 15 charts

Prostatic Neoplasms

NCT03043807 2023-02-16

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2 Completed

26 enrolled 8 charts

Prostatic Neoplasms

NCT04869371 2022-12-29

Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate Cancer

Phase 2 Unknown

Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel

NCT02598895 2022-11-17

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Phase 2 Completed

14 enrolled 8 charts

Prostatic Neoplasms